Latest Breaking News On - Patrick ritschel - Page 2 : vimarsana.com

Atsena expands leadership team with chief medical officer - People Moves - MM+M

Atsena expands leadership team with chief medical officer - People Moves - MM+M
mmm-online.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mmm-online.com Daily Mail and Mail on Sunday newspapers.

Patrick ritschelKenji fujitaAlnylam pharmaceuticalsAlexion pharmaceuticalsAtsena therapeuticsகெஞ்சி புஜிதாஅலெக்சியன் மருந்துகள்ஆட்சேண சிகிச்சை

Triangle s gene therapy hub has another rising star: Atsena, targeting blindness

by Chantal Allam, NCBiotech writer January 15, 2021 . DURHAM – There’s a new biotech startup in town, and it’s already generating a lot of buzz. Meet Atsena Therapeutics – a clinical-stage gene therapy company headquartered in Durham that’s on a mission to reverse and prevent blindness. Shortly after launching last April, it paid French pharmaceutical company Sanofi for exclusive rights to a gene therapy targeting Leber congenital amaurosis (LCA), a leading cause of blindness in children. That spurred investors to pour $55 million into Atsena – just months after it raised $8.2 million from investors including Durham’s Hatteras Venture Partners. Co-founder Shannon Boye, Ph.D. (left) with young LCA patient and his mom. (Atsena Therapeutics photo)

North carolinaUnited statesShannon boyeSanford boyePatrick ritschelCarolina biotechnology centerUniversity of floridaResearch triangleAtsena therapeuticsHatteras ventureNorth carolina biotechnologyTaysha gene therapiesBeam therapeuticsAsklepios biopharmaceuticalCo founder sanfordவடக்கு கரோலினா

Atsena Therapeutics Raises $55M in Series A Financing

Atsena Therapeutics, a Durham, N.C. and Boston, MA-based clinical-stage gene therapy company, closed a $55m Series A financing. The round was led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures and founding investors Hatteras Venture Partners and the Foundation Fighting Blindness’ RD Fund, and existing investors Osage University Partners, University of Florida, and Manning Family Foundation. In conjunction with the funding, Sarah Bhagat, PhD, Partner at Sofinnova, Jackie Grant, PhD, Principal at Abingworth, and Jason Lettmann, General Partner at Lightstone, will join Atsena’s board of directors. The company intends to use the funds to:

United statesJackie grantShannon boyeSanford boyeJason lettmannPatrick ritschelSarah bhagatManning family foundationUniversity of floridaOsage university partnersFoundation fighting blindnes rd fundAtsena therapeuticsSofinnova investmentsLightstone venturesHatteras venture partnersFoundation fighting blindnes

Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical . Atsena TherapeuticsDecember 16, 2020 GMT Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and all existing investors Company expands board of directors and plans to build out team DURHAM, N.C. and BOSTON, Dec. 16, 2020 (GLOBE NEWSWIRE) Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced it has closed an oversubscribed $55 million Series A financing led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures. Founding investors Hatteras Venture Partners and the Foundation Fighting Blindness’ RD Fund, along with existing investors Osage University Partners, University of F

United statesNorth carolinaCity ofUnited kingdomJackie grantShannon boyeJason lettmannSanford boyeTony plohorosPatrick ritschelSarah bhagatManning family foundationUniversity of floridaOsage university partnersFoundation fighting blindnes rd fundCarolina research triangle

Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid Development for Ocular Diseases

Published: Dec 16, 2020 DURHAM, N.C. and BOSTON, Dec. 16, 2020 (GLOBE NEWSWIRE) Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced it has closed an oversubscribed $55 million Series A financing led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures. Founding investors Hatteras Venture Partners and the Foundation Fighting Blindness’ RD Fund, along with existing investors Osage University Partners, University of Florida, and Manning Family Foundation, also participated in the round. Sarah Bhagat, PhD, Partner at Sofinnova, Jackie Grant, PhD, Principal at Abingworth, and Jason Lettmann, General Partner at Lightstone, will join Atsena’s board of directors.

United statesNorth carolinaCity ofUnited kingdomJackie grantShannon boyeJason lettmannSanford boyeTony plohorosPatrick ritschelSarah bhagatManning family foundationUniversity of floridaOsage university partnersFoundation fighting blindnes rd fundCarolina research triangle